Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Inventory (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Inventory for 16 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 10.5% to $20.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.8 million through Dec 2025, down 10.5% year-over-year, with the annual reading at $20.8 million for FY2025, 10.5% down from the prior year.
  • Inventory for Q4 2025 was $20.8 million at Harvard Bioscience, down from $21.6 million in the prior quarter.
  • The five-year high for Inventory was $29.3 million in Q2 2022, with the low at $20.8 million in Q4 2025.
  • Average Inventory over 5 years is $25.1 million, with a median of $25.5 million recorded in 2023.
  • The sharpest move saw Inventory grew 26.61% in 2022, then fell 16.88% in 2025.
  • Over 5 years, Inventory stood at $27.6 million in 2021, then dropped by 4.16% to $26.4 million in 2022, then fell by 6.52% to $24.7 million in 2023, then dropped by 5.95% to $23.2 million in 2024, then decreased by 10.5% to $20.8 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $20.8 million, $21.6 million, and $22.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.